CervoMed Inc
CRVO
Company Profile
Business description
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
Contact
20 Park Plaza
Suite 424
BostonMA02116
USAT: +1 617 744-4400
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
15
Stocks News & Analysis
stocks
The best way to get rich and retire early
This goes through the different options including shares, property and business ownership and declares a winner, as well as outlining the mindset needed to earn enough to never have to work again.
stocks
Investors overly negative on cheap ASX share
We cut our fair value by 26% but the market has overreacted.
stocks
Overvalued US AI play reports earnings
Strong earnings with high projected growth but price is too rich.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,032.00 | 53.10 | -0.58% |
| CAC 40 | 8,112.02 | 8.44 | 0.10% |
| DAX 40 | 24,351.12 | 11.06 | 0.05% |
| Dow JONES (US) | 48,450.37 | 260.60 | -0.53% |
| FTSE 100 | 9,866.53 | 4.15 | -0.04% |
| HKSE | 25,635.23 | 183.70 | -0.71% |
| NASDAQ | 23,431.21 | 161.89 | -0.69% |
| Nikkei 225 | 50,526.92 | 223.47 | -0.44% |
| NZX 50 Index | 13,525.99 | 3.07 | -0.02% |
| S&P 500 | 6,897.82 | 32.12 | -0.46% |
| S&P/ASX 200 | 8,725.70 | 51.00 | -0.58% |
| SSE Composite Index | 3,965.28 | 1.60 | 0.04% |